The lipid receptor G2A (GPR132) mediates macrophage migration in nerve injury-induced neuropathic pain

Tabea Osthues 1, Béla Zimmer 2, Vittoria Rimola 2, Kevin Klann 3, Karin Schilling 2, Praveen Mathoor 4, Carlo Angioni 2, Andreas Weigert 4, Gerd Geisslinger 1,2, Christian Münch 3,5, Klaus Scholich 1,2, Marco Sisignano 1,2,*

1 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany; Tabea.Osthues@ime.fraunhofer.de (T.O.); geisslinger@em.uni-frankfurt.de (G.G.); scholich@em.uni-frankfurt.de (K.S.)
2 Institute of Clinical Pharmacology, pharmazentrum frankfurt/ZAFES, University Hospital, Goethe-University, D-60590 Frankfurt am Main, Germany; Zimmer@med.uni-frankfurt.de (B.Z.); rimola@med.uni-frankfurt.de (V.R.); Schilling@med.uni-frankfurt.de (K.S.); angioni@em.uni-frankfurt.de (C.A.)
3 Institute of Biochemistry II, Faculty of Medicine, University Hospital, Goethe-University, D-60590 Frankfurt am Main, Germany; klann@em.uni-frankfurt.de (K.M.); ch.muench@em.uni-frankfurt.de (C.M.)
4 Institute of Biochemistry I, Faculty of Medicine, Goethe-University, D-60590 Frankfurt am Main, Germany; mathoor@biochem.uni-frankfurt.de (P.M.); weigert@biochem.uni-frankfurt.de (A.W.)
5 Cardio-Pulmonary Institute, D-60590 Frankfurt am Main, Germany
* Correspondence: Marco.Sisignano@med.uni-frankfurt.de; Tel.: +49-69-6301-87819

Abstract: Nerve injury-induced neuropathic pain is difficult to treat and mechanistically characterized by strong neuroimmune interactions, involving signaling lipids that act via specific G-protein coupled receptors. Here, we investigated the role of the signaling lipid receptor G2A (GPR132) in nerve injury-induced neuropathic pain using the robust spared nerve injury (SNI) mouse model. We found that the concentrations of the G2A agonist 9-HODE (9-Hydroxyoctadecadienoic acid) are strongly increased at the site of nerve injury during neuropathic pain. Moreover, G2A-deficient mice show a strong reduction of mechanical hypersensitivity after nerve injury. This phenotype is accompanied by a massive reduction of invading macrophages and neutrophils in G2A-deficient mice and a strongly reduced release of the proalgesic mediators TNFα, IL-6 and VEGF at the site of injury. Using a global proteome analysis to identify the underlying signaling pathways, we found that G2A activation in macrophages initiates MyD88-PI3K-AKT signaling and transient MMP9 release to trigger cytoskeleton remodeling and migration. We conclude that G2A-deficiency reduces inflammatory responses by decreasing the number of immune cells and the release of proinflammatory cytokines and growth factors at the site of nerve injury. Inhibiting the G2A receptor after nerve injury may reduce immune cell-mediated peripheral sensitization and may thus ameliorate neuropathic pain.

Keywords: neuropathic pain; 9-HODE; oxidized linoleic acid metabolites; macrophage migration; G2A; GPR132

1. Introduction

Neuropathic pain is a form of chronic pain induced by lesions, diseases, chemicals or tumor invasion of the somatosensory nervous system [1,2]. Neuropathic pain affects millions of people
worldwide and is difficult to treat due to lack of satisfactory medication and undesirable side effects [3–5].

Typical symptoms of neuropathic pain are allodynia—pain perception by harmless stimuli, hyperalgesia—increased pain perception by painful stimuli, or spontaneous pain [6–10]. Thereby, the normally high thresholds of peripheral nociceptors to mechanical and thermal stimuli are drastically reduced [9,11–13]. This peripheral sensitization is caused by neuroimmune interactions involving migration and infiltration of immune cells to the site of injury and the release of proinflammatory factors in nerve injury-induced neuropathic pain [6,11,14]. This interaction is known to modulate neuronal ion channels, such as the transient receptor potential vanilloid 1 (TRPV1) channel, thereby altering pain perception during neuropathic pain [6,12,13]. In nerve injury-induced neuropathic pain during the process of neuroimmune communication, signaling lipids play an important role and several lipid receptors have been identified as crucial mediators of onset, maintenance and resolution of different pathological pain states [15]. The linoleic acid metabolite 9-hydroxyoctadecadienoic acid (9-HODE) is the ligand of the G-protein coupled receptor G2A (GPR132), which is known to sensitize TRPV1 via Gq and activation of protein kinase C (PKC) [15–17]. G2A belongs to the group of proton-sensing GPCRs and is expressed in TRPV1-positive primary sensory neurons, but mainly in immune cells [18,19]. In the group of proton-sensing GPCRs, G2A shows the weakest response to acidic pH and seems to be a receptor for signaling lipids rather than for acidic conditions [20,21]. It has also been suggested before that G2A is responsible for the migration of leukocytes, but the underlying signaling pathways are still unclear [22–24].

The strong expression of this crucial lipid receptor in both sensory neurons and immune cells led us to the hypothesis that G2A is involved in immune cell migration and peripheral sensitization after nerve injury.

Here, we used the spared nerve injury, an acute neuropathic pain model with a strong inflammatory component, to investigate the role of G2A in neuropathic pain. We show that G2A-deficiency results in reduced mechanical hypersensitivity in vivo and leads to a markedly reduced number of immune cells and inflammatory mediators at the site of nerve injury, indicating a pivotal role of the G2A receptor in the initiation and progression of nerve injury-induced neuropathic pain.

2. Materials and Methods

2.1. Ethics Statement

All animals involved in the presented experiments were approved by the local Ethics Committees for Animal Research (Darmstadt, Germany) under the permit numbers FK/1046 and FK/1113. The animal experiments were performed according to the recommendations of the Guide of the Care and Use of Laboratory Animals of the National Institutes of Health (Guide for the Care and Use of Laboratory Animals, Washington, DC, USA, 2011). All efforts were made to minimize suffering.

2.2. Animals

In all behavioral experiments, wild-type and G2A-deficient mice with C57BL/6JRj background were matched in sex and age (9–16 weeks). Wild-type mice were purchased from commercial breeding companies (Janvier, Le Genest-Saint-Isle, France). The G2A-deficient mice were generated previously in the lab of Owen Witte, University of California (San Francisco) [25] and were bred at MFD diagnostics (Wendelsheim, Germany). During all behavioral experiments, the experimenter was blinded. Preclinical pain experiments were in accordance with the suggestions from the Preclinical Pain Research Consortium for Investigating Safety and Efficacy (PPRECISE) Working Group [26].

2.3. Spared Nerve Injury (SNI)

For behavioral experiments, spared nerve injury was performed. After anesthesia of the mice, the sciatic nerve was exposed by blunt dissection on the level of the knee joint. Then, the peroneal and
the tibial branches of the sciatic nerve were ligated with 6/0 non-sterile silk thread and cut distally from the ligature [27].

2.4. Behavioral Experiments

Determination of mechanical pain thresholds were performed by using a Dynamic Plantar aesthesiometer (Ugo Basile, Comerio, Italy). For this purpose, mice were sitting on an elevated grid in test cages for at least 1 h for accommodation before measurement. For baseline measurements, a steel rod was applied to the plantar side of the hind paw with linear ascending force (0–5 g over 10 s, in 0.5 g/s intervals). The time of the first contact of the steel rod until paw withdraw was measured in seconds (paw withdraw latency). Here, a cut-off time of 20 s was set [28]. After baseline measurements, the SNI surgery was performed followed by further dynamic plantar measurements.

2.5. Tissue Isolation

Mice were sacrificed and the sciatic nerve was dissected from injured (ipsilateral) and uninjured sites (contralateral) followed by freezing either in liquid nitrogen for RNA isolation or embedding in tissue tek (Sakura Finetek Europe, Alphen aan den Rijn, Netherlands) for slice preparation. Afterwards, the spinal cord of L1–L4 was dissected and incubated overnight in 20% sucrose solution at 4 °C. Then, the spinal cord was embedded vertically in tissue tek for following serial sections of 12 µm thickness by use of a cryostat (Leica, Frankfurt, Germany).

After dissecting the spinal cord, L4 to L6 DRGs were isolated and shock-frozen in fluid nitrogen for RNA isolation.

2.6. qRT-PCR

RNA was isolated from DRGs with a mirVana miRNA Isolation Kit (Applied Biosystems). Afterwards, RNA was quantified with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Waltham, MA, USA). 400 ng RNA was used for cDNA synthesis. For reverse transcription, the First Strand cDNA Synthesis Kit was used according to the manufacturer’s description. For the following qPCR, a TaqMan® Gene Expression Assay System was used according to the manufacturers description (Thermo Scientific, Waltham, MA, USA) and as previously reported [29]. Afterwards, the qPCR program was conducted with the QuantStudio™ Design and Analysis Software v1.4.3 (Thermo Fisher) and evaluated using the \( \Delta\Delta C(T) \) method, as described previously [30].

2.7. Immunohistochemistry

For immunohistochemical staining, spinal cord or nerve tissue was prepared into 12 µm slices. The slices were fixed with 2% PFA in PBS (pH 7.4) for 20 min. After washing the slices for 5 min with PBS, they were permeabilized in PBST (PBS + 0.1% triton X) for 10 min. Then, samples were blocked for 45 min in 3% BSA in PBST. As first antibodies, GFAP (NB300-141, novusbio, Centennial, CO, USA) in 1:1000 dilution for spinal cord or F4/80 (ab6640, abcam, Cambridge, UK) and CD11b (ab133357, abcam) in 1:100 dilution for nerve were used. After incubation over night at 4 °C, the second antibodies, anti-rabbit Cy 3 (C2306-1ML, Sigma, Deisenhofen, Germany) and anti-rat AF488 (ab150157, abcam), were incubated in a dilution of 1:1000 at room temperature for 1 h. Afterwards, the slices were stained with DAPI 1:1000 (6335.1, Carl Roth, Karlsruhe, Germany). Pictures of the stained slices were taken with the fluorescence microscope Observer.Z1 (Carl Zeiss, Oberkochen, Germany) [31].

2.8. ELISA and Multiplex Assays

For protein detection, dissected nerve tissues were chopped, spinal cord samples were pottered, and afterwards, DRG, spinal cord and nerve samples were sonicated (2 × 60%, 10 s) in 100–500 µL of, respectively, cell lysis buffer, a mixture of phosphosate (Merck, Darmstadt, Germany) and protease-inhibitor (Roche Holding AG, Basel, Switzerland) or ice-cold PBS (R&D systems, Minneapolis,
Cells 2020, 9, 1740 4 of 20

MN, USA/Ray Biotech, Peachtree Corners, GA, USA). Afterwards, the samples were centrifuged for 10 min at 10,000 rpm. The supernatant was then used for Bradford (Sigma-Aldrich) measurements, as described previously (Bradford 1976), followed by IL-1β (R&D systems, Minneapolis, Minnesota, USA), IL-6, TNFα (Ray Biotech), NGF (DLDevelop, Wuxi, Jiangsu, China), ELISA or Luminex Multiplex measurements (Invitrogen, Carlsbad, CA, USA). In the Luminex Multiplex measurement, the following cyto- and chemo-kines were measured: FGFβ, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), IL-13, II-17, IP-10, KC, MCP-1, MIG, MIP-1α, TNF-α and VEGF. The different ELISAs and the Luminex Multiplex were performed according to the manufacturer’s description. All samples were measured in duplicates. For calculation of the protein concentrations, Graph Pad Prism 7 was used.

2.9. Differentiation and Stimulation of Bone Marrow-Derived Macrophages

Mice were sacrificed, and the hind legs were dissected from the body and transferred into PBS. The bones were cleaned from muscle tissue, cut open and then centrifugated (13,000 rpm, 1 min, RT) to isolate the bone marrow. Afterwards, 12.5 mL medium (RPMI 1640—GlutaMAX™-I, Invitrogen, Carlsbad, USA, with 10% FCS, 1% penicillin/streptomycin) was mixed with 0.2 µL/mL M-CSF (100 µg/mL, Preprotech, Hamburg, Germany) and used for resuspension of the bone marrow. Afterwards, the suspension was transferred to a 6-well plate. Cells were incubated over night at 37 °C and cultivated for seven days, as previously described [22].

Then cells were stimulated with 1 µM 9 HODE for 0, 5, 10 and 15 min, or 24 h. Afterwards, cells were harvested with a cell scraper in 50:50 Phosphosafe:cOmplete protease-inhibitor cocktail (100 µL/well). Then, the cells were sonicated twice (60%, 10 s) and total protein amount was determined by Bradford Protein Assay [16,22,32].

2.10. Proteome Analysis

2.10.1. Sample Preparation for LC-MS²

Proteomics were performed as previously described with some adjustments [33]. Lysates were precipitated using 3 volumes of ice-cold methanol, 1 volume Chloroform and 2.5 volumes ddH2O. After centrifugation (14,000× g, 45 min, 4 °C), the upper aqueous phase was aspirated, and 3 volumes of ice-cold methanol were added. Samples were mixed and proteins pelleted by centrifugation (14,000× g, 5 min, 4 °C). The pellets were washed with ice-cold methanol. Protein pellets were dried at RT and then resuspended in 8 M Urea, 10 mM EPPS pH 8.2 and 1 mM CaCl₂, followed by protein concentration determination using a µBCA assay (ThermoFisher Scientific, 23235). Samples were then diluted to 2 M urea using digestion buffer (10 mM EPPS pH 8.2, 1 mM CaCl₂) and incubated with the endoproteinase LysC (Wako Chemicals, Neuss, Germany) at a 1:50 (w/w) ratio overnight at 37 °C. Then, digestion reactions were diluted to 1 M Urea using digestion buffer and incubated at a 1:100 (w/w) ratio of trypsin (V5113, Promega, Madison, WI, USA) for 6 h at 37 °C. Digests were acidified to a pH of 2–3 using trifluoroaceticacid (TFA). Peptides were purified with SepPak tC18 columns (WAT054955, Waters Milford, MA, USA) according to the manufacturer’s instructions. Eluates were dried and peptides were resuspended in TMT labeling buffer (0.2 M EPPS pH 8.2, 10% Acetonitrile). Peptide concentration was determined by µBCA. Peptides were mixed with TMT reagents (ThermoFisher Scientific, 90111, A37724, 90061) at 1:2 (w/w) (2 µg TMT reagent per 1 µg peptide). Reactions were incubated (1 h, RT) and subsequently quenched by addition of hydroxylamine to a final concentration of 0.5% (15 min, RT). Samples were pooled in equimolar ratio (unless stated otherwise), acidified, and dried.

Before MS-analysis and fractionation, peptide samples were purified using either Empore C18 (Octadecyl) resin material (3M Empore) or tC18 SepPak (50mg, Waters). Material was activated by incubation with Methanol for 5 min, followed by washing each with 70% acetonitrile/0.1% TFA and 5% acetonitrile/0.1% TFA. Samples were resuspended in 5% acetonitrile, 0.1% TFA and loaded to resin
material. Peptides were washed with 5% acetonitrile/0.1% TFA and eluted with 70% acetonitrile (ACN). Samples were dried for future use.

2.10.2. High-pH Reverse Phase Fractionation

For high-pH reversed phase fractionation on the Dionex HPLC, 500 µg of pooled and purified TMT-labelled samples were resuspended in 10 mM ammonium-bicarbonate (ABC), 5% ACN, and separated on a 250 mm long C18 column (Aeris Peptide XB-C18, 4.6 mm ID, 2.6 µm particle size; Phenomenex, Aschaffenburg, Germany) using a multistep gradient from 100% Solvent A (5% ACN, 10 mM ABC in water) to 60% Solvent B (90% ACN, 10 mM ABC in water) over 70 min. Eluted peptides were collected every 45 s into a total of 96 fractions, which were cross-concatenated into 12 fractions and dried.

2.10.3. LC-MS

Peptides were resuspended in 0.1% FA and separated on an easy nLC 1200 (ThermoFisher Scientific) and a 22 cm long, 75 µm ID fused-silica column, which has been packed in house with 1.9 µm C18 particles (ReproSil-Pur, Dr. Maisch, Ammerbruch-Entringen, Germany), and kept at 45 °C using an integrated column oven (Sonation). Peptides were eluted by a non-linear gradient from 5–38% acetonitrile over 120 min and directly sprayed into a Fusion Lumos mass spectrometer equipped with a nanoFlex ion source (ThermoFisher Scientific) at a spray voltage of 2.6 kV. Full scan MS spectra (350–1400 m/z) were acquired at a resolution of 120,000 at m/z 200, a maximum injection time of 100 ms and an AGC target value of 4×105 charges. MS2 scans were performed for up to the 10 most intense ions in the IonTrav (Rapid), with an isolation window of 0.7 Th, a maximum injection time of 85 ms, and CID-fragmented using a collision energy of 35% for 10 ms. SPS-MS3 was performed on the 10 most intense MS2 fragment ions with an isolation window of 0.7 Th (MS1) and 2 m/z (MS2). Ions were fragmented using HCD with a normalized collision energy of 65 and analyzed in the Orbitrap with a resolution setting of 50,000 at m/z 200, scan range of 110–500 m/z, AGC target value of 1×105 and a maximum injection time of 86 ms. Dynamic exclusion was set to 45 s to minimize repeated sequencing of already acquired precursors. Raw filed data were processed with Proteome Discoverer 2.2 software and searched against the mouse SwissProt reference database, including isoforms (2018-12-10) and common contaminants. PSMs were filtered for a co-isolation threshold of 50% and an average reporter S/N of at least 10. For quantification, only unique peptides were considered, and data was corrected for impurities according to Lot-number and normalized using the total peptide amount to account for unequal loading in the TMT multiplex.

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (Proteomics Identifications Database) with the dataset identifier PXD019836 [34].

2.11. Western Blot

For Western Blot analysis, 20 to 30 µg of protein of treated bone marrow-derived macrophages were separated by SDS-polyacrylamide gel electrophoresis (4% stacking gel, 12% running gel). Blotting of the proteins was performed using the Trans-Blot® Turbo™ Transfer System (BioRad, Hercules, CA, USA) and a nictrocellulose membrane (Sigma-Aldrich, St. Louis, Missouri, USA).

 Afterwards, the membrane was blocked with 5% milk powder in TN buffer for 2 h following antibody incubation over night at 4 °C: p-ERK 1:1000 (4377S, Cell Signaling, Frankfurt am Main, Germany), ERK 1:1000 (sc-1647, Santa Cruz Biotechnology, Dallas, TX, USA), p-p38 1:1000 (9211, Cell Signaling, Frankfurt am Main, Germany), p-38 1:1000 (9212, Cell Signaling), ROCK-1 1:500 (ab45171, abcam), ROCK-2 1:500 (ab71598, abcam), Transgelin 1:1000 (NB600-507, novusbio), PTK7 1:500 (AF4499, R&D Systems), MMP9 1:1000 (AF909, R&D Systems), ITGA2B 1:1000 (orb376331, biorbyt, Cambridge, UK), CXCR4 1:1000 (BS-1011R, biosantibodies, Woburn, MA, USA), ELMO-1 (ab2239, abcam). As loading controls, either HSP90 1:1000 (sc-13119, Santa Cruz, Dallas, TX, USA) or GAPDH 1:1000.
Cells 2020, 9, 1740 6 of 20
(ab8245, abcam) were used. Detection of proteins was performed with HRP-coupled secondary antibodies in a dilution of 1:5000 (ab97110, abcam; A9169-2ML and A9044-2ML, Sigma-Aldrich) and an ECL reagent (Thermo Scientific) [35]. Quantification of protein amount was determined by densitometrical analysis with GelAnalyzer 2010 software [36].

2.12. Fluorescence-Activated Cell Sorting (FACS) Analysis

Single-cell suspension of ipsi- and contra-lateral nerves, spinal cord and L4–L6 DRGs were generated by chopping the nerves into small pieces, mincing the spinal cord and then incubating all the tissues in DMEM (Invitrogen) with 3 mg/mL collagenase (Sigma) and 1 µL/mL DNase (Promega) (30 min, 37 °C, 95% O2) with shaking the samples every 10 min. Afterwards, DMEM with 10% FCS was added to the samples. Samples were then transferred through a 70 µm filter. The filter was washed with 0.5% BSA (Sigma) in PBS. Afterwards, cells were centrifuged (400×g, 5 min) and washed with 0.5% BSA in PBS. Single-cell suspensions were blocked with FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) in 0.5% PBS-BSA for 20 min, stained with fluorochrome-conjugated antibodies and analyzed on a LSR II/Fortessa flow cytometer or sorted using a FACS Aria III sorter (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using FlowJo V10 (TreeStar). All antibodies and secondary reagents were titrated to determine optimal concentrations. Comp-Beads (BD) were used for single-color compensation to create multicolor compensation matrices. For gating, fluorescence minus one controls were used. The instrument calibration was controlled daily using Cytometer Setup and Tracking beads (BD Biosciences). For characterization of immune cell subsets in nerve, DRGs or spinal cord, the following antibodies were used: anti-CD3-PE-CF594, anti-CD4-V500, anti-CD11b-BV605, anti-CD11c-AlexaFluor700, anti-CD19-APC-H7, anti-Ly6C-Per-CP-Cy5.5, anti-NK1.1 PE (BD Biosciences), anti-F4/80-PE-Cy7, anti-GITR-FITC and anti-Ly6G-APC-Cy7 (BioLegend, San Diego, CA, USA) [37].

2.13. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for the Determination of Lipid Mediators

The following reference substances as well as their deuterated analogues used as internal standards were purchased from Cayman Chemical (Ann Arbor, USA): 9(10)- and 12(13)-EpOME, (epoxyoactadecenoid acid) 9,10- and 12,13—DiHOME dihydroxyoactadecenoic acids), 9- and 13-HODE, (hydroxyoactadecenoic acid), 5,6-, 8,9-, 11,12- and 14,15-EpETrE (EET, epoxyeicosatrienoic acids), 5,6-, 8,9-, 11,12- and 14,15-DiHETrE (DHET, dihydroxyeicosatrienoic acids), 17(18)-EpETrE (EEQ, epoxyeicosatetraenoic acid) and 19(20)-EpDPA (EDP, epoxydocosapentaenoic acid).

After dissecting the contralateral and ipsilateral sides of sciatic nerve, the L4–L6 dorsal root ganglia and the spinal cord from euthanized animals, the samples were directly frozen in liquid nitrogen. The tissue weight was determined, and lipid quantification was performed as described previously [16,38]. Briefly, tissue samples were homogenized using a swing mill and analytes were extracted from homogenates using liquid–liquid extraction with ethyl acetate after spiking with a mixture of the deuterated internal standards. After liquid–liquid extraction, combined organic phases were removed at a temperature of 45 °C under a gentle stream of nitrogen. The residues were resuspended in 50 µL of methanol/water/BHT (50:50:10−4, v/v/v), then centrifuged for 2 min at 10,000×g and transferred to glass vials (Ziemer GmbH, Langenwehe, Germany).

For calibration, PBS samples were spiked with working solutions of the analytes (prepared in methanol/BHT (100:0.1 v/v)) and processed as described for the homogenates. The LC-MS/MS system consisted of a triple quadrupole tandem mass spectrometer QTRAP 5500 (Sciex, Darmstadt, Germany) equipped with a Turbo-V source operating in negative electrospray ionization mode, an Agilent 1200 binary HPLC pump and degasser (Agilent, Waldbronn, Germany) and a HTC Pal autosampler (CTC analytics, Zwingen, Switzerland).
Chromatographic separation of the lipids was performed using a Gemini NX C18 column and precolumn (150 × 2 mm inner diameter, 5 µm particle size and 110 Å pore size; Phenomenex) and a linear gradient using a flow rate of 0.5 mL/min in a total run time of 17.5 min. Thereby, the gradient changed from 85% mobile phase A (water:ammonia 100:0.05, v/v), to 10% A and 90% mobile phase B (acetonitrile:ammonia 100:0.05, v/v). The conditions were held for 1 min until the mobile phase shifted back to 85% A. These conditions were maintained for 4 min to re-equilibrate the column.

Analyst software version 1.6.3 (Sciex) was used for data acquisition, while further quantification was performed with Multiquant Software version 3.0.2 (Sciex) using the internal standard method (isotope-dilution mass spectrometry). Calibration curves were calculated by linear regression with 1/concentration weighting.

2.14. Data Analysis and Statistics

All data are presented as mean ± SEM. Determination of statistically significant differences in all behavioral experiments was conducted with two-way analysis of variance (ANOVA) followed by post hoc Bonferroni correction using GraphPad Prism 7. For in vitro experiments comparing only two groups, Student’s t test was carried out with Welch’s correction, and for comparing more than two groups, one-way ANOVA was used. The comparison of more groups with different conditions, including behavioral experiments, was performed with two-way ANOVA followed by post hoc Bonferroni or Holm-Sidak correction. A p-value of <0.05 was considered statistically significant. Lipidomic data were tested for normal distribution with the Shapiro–Wilk Test using GraphPad Prism 7 and all datasets passed the test (W > Wα; α = 0.05).

3. Results

3.1. Loss of G2A Alleviates Mechanical Hypersensitivity and Alters Lipid Signaling

We previously showed that activation of G2A in sensory neurons leads to an increased mechanical pain hypersensitivity during oxaliplatin-induced neuropathic pain due to sensitization of TRPV1 [16]. However, G2A is also strongly expressed in immune cells, such as macrophages, neutrophils and T-cells [18,39]. We therefore wanted to investigate the role of G2A in a neuropathic pain model with a strong inflammatory component. Since peripheral nerve injury-induced neuropathic pain is characterized by a strong immune cell infiltration from day 4, ongoing and lasting for over 21 days [40,41], we chose the robust spared nerve injury (SNI) model [27]. After performing the SNI surgery, we analyzed the paw withdrawal reflex of the mice for seven days. We found that G2A-deficiency resulted in a significant decrease of mechanical hypersensitivity from starting at day 2 compared with wild-type mice (Figure 1A).
Figure 1. GPR132 (G2A)-deficiency leads to reduced mechanical hypersensitivity and the secretion of oxidized lipids is affected in wild-type mice. (A) Paw withdraw latency (PWL) of ipsilateral site of wild-type mice (WT, triangle), G2A-deficient mice (G2A\(^{-/-}\), squares) and sham-treated mice (circles) after spared-nerve injury (SNI) surgery. n = 10 animals, male and female, \(* p < 0.05, ** p < 0.01, *** p < 0.001 (WT vs. G2A\(^{-/-}\)); ### p < 0.005, #### p < 0.0001 (WT vs. sham); $$ p < 0.01, $$$ p < 0.005, $$$$ p < 0.0001 (G2A\(^{-/-}\) vs. sham). Statistics were performed with two-way Analysis of variance (ANOVA) with Bonferroni correction. (B) Schematic depiction of the oxidative linoleic acid pathway. (C,D) Concentrations of 9-hydroxyoctadecadienoic acid (HODE) in sciatic nerve (SN), L4–L6-dorsal root ganglia (DRG) and spinal cord (SC) in wild-type (C) and G2A-deficient (G2A\(^{-/-}\)) (D) mice 7 days after SNI surgery. (E, F) Concentrations of 13-HODE in sciatic nerve (SN), dorsal root ganglia (DRG) and spinal cord (SC) in wild-type (E) and G2A-deficient (G2A\(^{-/-}\)) (F) mice 7 days after SNI surgery. (G–J) Concentrations of epoxyoctadecenoic acids (EpOMEs) and dihydroxyoctadecenoic acids (DiHOMEs) in SN (G, H) and DRG (IJ) in wild-type (G, I) and G2A\(^{-/-}\) (H, J) mice 7 days after SNI surgery. Black represents untreated site (contralateral). Grey represents treated site (ipsilateral) in the respective tissues from n = 5 mice per group, male and female. Data represent mean ± standard error of mean (SEM). \(* p < 0.05, ** p < 0.01, *** p < 0.005; Two-way ANOVA with the Holm-Sidak method.
At the site of injury, immune cells are recruited and activated, stimulating peripheral sensory neurons to release endogenous factors, such as lipid mediators [6,10,42]. Since G2A is a lipid receptor, we investigated whether or not the levels of lipids known to activate G2A as well as their metabolites were altered during SNI-induced neuropathic pain in nervous tissue. Therefore, we performed LC-MS/MS-based targeted analysis. We observed that the linoleic acid metabolites 9- and 13-HODE were increased at the injured nerves in wild-type mice 7 days after the SNI surgery (Figure 1C,E), both of which are endogenous agonists of G2A (Figure 1B). Moreover, we could detect a strong increase of the lipid 12,13-epoxyoctadecenoic acid (EpOME) in the injured ipsilateral site of the nerve, which was recently identified as weak G2A agonist (Figure 1G) [43]. In contrast, G2A-deficient mice did not show any difference between the treated (ipsilateral) and untreated sites (contralateral) regarding the different lipid concentrations (Figure 1D,F,H,J). In DRG tissue of wild-type mice, the DiHOMEs showed an increased level at the ipsilateral site, indicating a strong involvement of soluble epoxide hydroxylase (sEH) in the DRGs (Figure 11) [44]. Similar results were observed 24 h after zymosan-induced inflammatory pain and also 7 days after CFA-induced inflammation in DRGs [45]. This indicates a role for 12,13-DiHOME in pain processing since it also showed decreased amounts in the sciatic nerve in G2A-deficient mice (Figure 1H).

3.2. G2A-Dependent Alterations of Immune Cell Recruitment and Cytokine Synthesis in Nociceptive Tissue

Since G2A agonists were upregulated in the different nociceptive tissues, we next analyzed the number of immune cells along the stations of nociceptive processing. Using multiparameter FACS analysis, we observed an infiltration of various immune cells in general in wild-type mice at the site of injury of the sciatic nerve (SN) 7 days after SNI surgery (Figure 2A). The infiltration of immune cells to the DRGs and the spinal cord after nerve injury has been demonstrated before and usually peaks around days 5–10 after surgery [46–49]. Based on these observations, we considered 7 days after surgery an appropriate timepoint to investigate immune cell infiltration into nervous tissue.

Interestingly, G2A-deficient mice showed a 5- to 10-fold reduced number of immune cells (CD45-positive cells) at the site of injury in SN (Figure 2A–C). However, the strongest differences were observed in the number of macrophages and neutrophils in sciatic nerve (SN) (Figure 2B). Here, the number of macrophages was 12-fold lower at the site of injury in G2A-deficient mice than in wild-type mice, which could be confirmed with immunohistochemistry staining for F4/80 and CD11b (Figure 2D,E). Likewise, the number of neutrophils was 7-fold lower in G2A-deficient mice (Figure 2B). Next to this, the number of dendritic cells (DC), CD11b+ NK cells, NK cells and T cells revealed a decrease in G2A-deficient mice as well, in ipsilateral SN (Figure 2C).

In L4–L6-DRGs, the number of infiltrated immune cells was smaller than in SN (Figure 2A–H). As the FACS analysis revealed, the number of infiltrated CD45+ immune cells was decreased in G2A-deficient mice 7 days after SNI surgery (Figure 2F). Next to this, only the macrophages and neutrophils showed a significantly decreased number in G2A-deficient mice (Figure 2G). However, the number of macrophages was not as strongly decreased as in the sciatic nerve (Figure 2B,G). Moreover, the number of neutrophils was also decreased in DRGs, compared to SN in G2A-deficient mice 7 days after SNI (Figure 2B,G). However, the other immune cell types showed no differences in DRGs in both genotypes (Figure 2H).

Interestingly, the infiltration of immune cells into the spinal cord was in total 10-fold lower than in the sciatic nerve and 3.5-fold smaller than in DRGs (Figure 2A,F,J). Nevertheless, the CD45+ immune cells in spinal cord also showed a decreased number in G2A-deficient mice 7 days after SNI (Figure 2I). However, only the number of macrophages were significantly decreased in spinal cord in G2A-deficient mice, compared to wild-type mice (Figure 2J).
Figure 2. Reduced number of immune cells in G2A-deficient mice 7 days after SNI surgery. (A) Total immune cell number at the ipsi- and contra-lateral site of sciatic nerve (SN) (CD45+). (B,C) Number of different types of immune cells in the ipsi- and contra-lateral site of the sciatic nerve. (D,E) Immunohistochemical staining of macrophages (F4/80, CD11b) at the injured sciatic nerve (SN) in wild-type (D) and G2A-deficient mice (E) 7 days after SNI. Dashed lines indicate sites of injury. (F) Total immune cell number in L4–L6-DRGs at the ipsi- and contra-lateral site of sciatic nerve. (G,H) Number of different types of immune cells in the ipsi- and contra-lateral site of L4–L6-DRGs 7 days after SNI surgery. (I) Total immune cell number in the dorsal spinal cord receiving input from spinal cord comparing the ipsi- and contra-lateral site. (J,K) Number of different types of immune cells in the dorsal spinal cord section receiving input from L4–L6-DRGs comparing the ipsi- and contra-lateral site 7 days after SNI surgery. Data were obtained from n = 5 animals per group, male and female. Ipsilateral site of WT mice is shown in black. Ipsilateral site in SN is shown in yellow, in DRG in purple and in SC in green. Contralateral site of WT mice is depicted in dark grey. Contralateral site of G2A−/− mice is shown in light grey. Neutrophils (CD45+, Ly6G+, CD11b+), macrophages (CD45+, Ly6G−, CD11b+, F4-80+, Ly6C−), monocytes (CD45+, Ly6G−, CD11b+, F4-80−, Ly6C+), dendritic cells (DC; CD45+, Ly6G−, CD11b+, F4-80+, Ly6C−, CD11c+, MHCIi+), CD11b+ NK cells (CD45+, Ly6G−, CD11b+, F4-80−, Ly6C−, NK1.1+), NK cells (CD45+, Ly6G−, CD11b−, F4-80−, Ly6C+, NK1.1+), T cells (CD45+, Ly6G−, CD11b−, F4-80−, CD3+, MHCIi+), CD4 T cells (CD45+, Ly6G+, CD11b+, F4-80−, CD3+, MHCIi+), CD8 T cells (CD45+, Ly6G−, CD11b−, F4-80−, CD3−, MHCIi+), CD8 T cells (CD45+, Ly6G−, CD11b−, F4-80−, CD3−, MHCIi+), CD8+ T cells (CD45+, Ly6G−, CD11b−, F4-80−, CD3−, MHCIi+), CD8+ T cells (CD45+, Ly6G−, CD11b−, F4-80−, CD3−, MHCIi+), CD8+ T cells (CD45+, Ly6G−, CD11b−, F4-80−, CD3−, MHCIi+). Data represents mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001; Two-way ANOVA with Bonferroni correction.
There was no difference observed comparing astrocyte activation between the genotypes 7 days after SNI, which is known to be characteristic in neuropathic pain [50] (Figure 2I–K, Supplementary Figure S1).

In conclusion, we saw differences in the number of immune cells, especially macrophages, mainly at the site of injury. The differences in immune cell infiltration between the genotypes were smaller in DRGs and in the spinal cord (Figure 2).

The reduced number of immune cells, especially at the site of injury, lead us to the hypothesis that the levels of cytokines, chemokines and growth factors, known for modulating neuropathic pain [9,11], may also be altered in G2A-deficient mice after SNI surgery. We therefore performed an unbiased screen of growth factors, chemokines and cytokines, which are known for their role in inflammation, which was previously shown in a SNI model [41] (Figure 3A). In this screen, we observed decreased concentrations of tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) in ipsilateral sciatic nerves of G2A-deficient mice compared to wild-type mice (Figure 3B,C). These two signaling molecules have been connected with persistent pain states before and are known mediators of both peripheral and central sensitization [51]. The cytokines GM-CSF, IFNγ, IL-4, IL-10, MCP-1 and MIP were not detectable in any tissue measured (data not shown). Additionally, the concentrations of nerve growth factor (NGF), which is a very important factor released upon injury and inflammation contributing to pain initiation [12,14], as well as the anti-inflammatory cytokine TGFβ, did not show any differences when comparing wild-type and G2A-deficient mice (Figure 3D,E). NGF expression is known to be increased by pro-inflammatory cytokine IL-1β [11,14], but IL-1β also showed no difference between both genotypes at the ipsilateral site of injured nerves, nor was a general difference in G2A expression detectable in DRGs after surgery (Supplementary Figure S2).

**Figure 3.** Reduced concentrations of inflammatory cytokines in G2A-deficient mice. (A) Heat map of cytokines levels in sciatic nerve, DRG and spinal cord at the ipsilateral site of wild-type and G2A-deficient mice 7 days after SNI. Data shown as ipsi-lateral of WT vs. ipsi-lateral of G2A-deficient mice measured with LUMINEX. (B–F) Concentrations of tumor necrosis factor alpha (TNFα) (B), interleukin 6 (IL-6) (C), nerve growth factor (NGF) (D), transforming growth factor beta (TGFβ) (E) and IL-1β (F) in the ipsilateral site of sciatic nerve 7 days after SNI in wild-type (WT, black) and G2A-deficient mice (G2A−−, yellow in sciatic nerve), measured with enzyme-linked immunosorbent assay (ELISA). Data represent mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001 of n = 5 mice per group, male and female; one-way ANOVA.
In L4–L6 DRG, we observed a decreased amount of the cytokine IL-12 in G2A-deficient mice (Figure 3A). However, the expression of either IL-12a (data not shown) or IL-12b remained unaltered (Supplementary Figure S2), indicating that neuronal G2A is unaffected by SNI surgery. Oxidative stress is an important contributor to nerve injury-induced neuropathic pain. However, oxidative stress markers such as inducible NO synthase (iNOS), NADPH oxidase (Nox)-2 and Nox-4 did not show any alterations in mRNA expression in wild-type and G2A-deficient mice (Supplementary Figure S3). In contrast, the established neuronal stress marker ATF3 (activating transcription factor 3) was increased 7 days after SNI (Supplementary Figure S3B).

To investigate whether or not these differences between the genotypes are caused by the surgery itself, we also measured immune cell number, cytokine, chemokine and growth factor concentrations between the two genotypes 1 day after SNI surgery. At this time point, no differences were found between the genotypes in ipsilateral sites, either in the number of immune cells or the amount of various cyto- and chemo-kines in SN, DRGs or SC (Supplementary Figure S4). These data suggest that surgery-induced acute recruitment of immune cells is not G2A-dependent and that the differences between the genotypes require a neuropathic component that develops several days after nerve-injury.

3.3. Migration of Macrophages is Impaired by Loss of G2A Receptor

Since the number of macrophages was dramatically decreased in G2A-deficient mice in all three investigated tissues (sciatic nerve, DRGs and spinal cord), we hypothesized that G2A-deficiency affects the immunomodulatory and migratory properties of macrophages [22]. Therefore, we performed a global proteome analysis using a vanguard mass-spectrometry-based approach [33] using bone marrow-derived macrophages (BMDM) of wild-type and G2A. The BMDMs were stimulated with the G2A agonist 9-HODE (1 µM) for 24 h prior to the proteomic analysis. This concentration is in range of the EC50 of 9-HODE for both the human and the murine G2A, as previously shown [16,21]. The stimulation of BMDMs with 9-HODE induced a minor, but significant increase of G2A mRNA expression (Figure 4A).

![Figure 4](image-url)
9-HODE for 24 h. n = 6–10 animals per group, male. (B) Identification of 6,000 regulated proteins 24 h after stimulation with 1 µM 9-HODE in BMDMs. Fold change (FC) [log2] is plotted against p-values [Log10]. Significant downregulated proteins are depicted in blue, and red represents upregulated proteins. (C) Percentage of downregulated proteins 24 h after 1 µM 9-HODE stimulation compared to untreated BMDMs. (D) Percentage of upregulated proteins 24 h after 1 µM 9-HODE stimulation compared to untreated BMDMs, clustered in groups. Yellow: immune system, blue: lipid metabolic process, brown: adhesion, green: migration, grey: apoptosis, pink: lysosome, red: inflammation, white: hematopoiesis, black: other. Data represents mean ± SEM. * p < 0.05. An unpaired one-tailed t-test was used for statistics.

Global proteome analysis revealed significant changes in protein levels in wild-type mice after G2A activation through 9-HODE (Figure 4B). Among the strongest upregulated proteins were protein tyrosine kinase 7 (PTK7), catenin alpha-1 (Ctnna1), alpha actinin 1 (Actn1), myeloid differentiation primary response protein (Myd88), transgelin (Tagln) and phosphoinositide 3-kinase (PI3K) subunits, which are known to play central roles in migration (Figures 4B and 5A, Supplementary Table S1C) [52–57]. Proteins like caspase 8, cathepsines and Gadd45 were the proteins with the strongest downregulation (Figure 3C, Supplementary Table S1E). These proteins are known to play a central role during apoptosis [58,59]. Interestingly, proteins concerning hematopoiesis were rather downregulated, including CD38 (Figure 4C, Supplementary Table S1F), which is in line with previous observations showing that G2A receptor affects hematopoiesis in vivo [43].

Figure 5. Transient increase of matrix-metalloproteinase 9 (MMP9) secretion and MMP9 downregulation in BMDMs 24 h after G2A activation. (A) List of the strongest upregulated migratory proteins in WT 24 h after 1 µM 9-HODE stimulation. (B) Comparison of the strongest upregulated migratory proteins in WT and G2A-deficient (G2A−/−) BMDMs regarding the toll-like receptor 4 (TLR4)-signaling pathway shown as -log p-value. (C) Scheme of possible G2A–TLR4 interaction and signaling in BMDMs. (D) List of the 10 strongest downregulated migratory proteins in WT 24 h after 1 µM 9-HODE stimulation. (E) Representative Western Blots of MMP9 expression and respective analyzed data in untreated and treated BMDMs with 1 µM 9-HODE. (F) MMP9 expression in BMDM lysates treated with 1 µM 9-HODE for different time points. (G) MMP9 secretion of BMDMs treated with 1 µM 9-HODE for different time points. Analyzed with ELISA. n = 6–10 male animals per group. Data represents mean ± SEM. * p < 0.05, ** p < 0.01. An unpaired one-tailed t-test and a One-way ANOVA were used.
3.4. Is Macrophage Migration Affected by MMP9 Regulation?

Among the strongest regulated proteins known to mediate migration were proteins connected to the Toll-like receptor 4 (TLR4) signaling pathway, such as MyD88, PI3K and Dock2 (Figure 5B,C), as well as matrix-metalloproteinase 9 (MMP9) (Figure 5D, E). This finding was especially surprising, since MMP9 is a key molecule in macrophage migration in the tissues, due to its ability to destroy extracellular matrix [60].

However, MMP9 downregulation in BMDMs after 24 h of G2A-activation through 9-HODE was confirmed by Western blot and with ELISA (Figure 5E, F). Interestingly, in a time-dependent stimulation study, MMP9 secretion was significantly increased 4, 6 and 10 h after 9-HODE stimulation (Figure 5G). Whereas, in BMDM lysates, MMP9 expression decreased over time, which is in line with an increased secretion (Figure 5F). Other pro-migratory proteins, such as MAP-kinases, ROCK, Ras and Rac were not affected by 9-HODE stimulation nor were there any differences between the genotypes (Supplementary Figure S5, Supplementary Table S2).

4. Discussion

In this study, we showed that loss of G2A alleviated mechanical hypersensitivity in acute nerve injury-induced peripheral neuropathic pain. As the results suggest, this is likely due to an altered neuroimmune response accompanied by a reduced immune cell infiltration to the injured nerve. Thereby, the concentrations of established inflammatory mediators released by immune cells, such as IL-6 and TNFα, but also of oxidized lipid mediators like 9- and 13-HODE (Figures 1–3) are markedly decreased at the injured sciatic nerve of G2A-deficient mice.

For the sensitizing effects of 9-HODE, its receptor G2A seems to be required, which is induced during cellular stress and DNA damage [16, 61]. Since nerve injury is stress for cells and tissues, it is not surprising that the expression of the known neuronal stress marker ATF3 was increased 7 days after SNI (Supplementary Figure S3B) [62]. However, stress markers were not differentially expressed between the genotypes, indicating no effect on cellular stress due to G2A-deficiency.

G2A-deficient mice showed less mechanical hypersensitivity in an oxaliplatin-induced neuropathic pain model, suggesting an anti-nociceptive effect of G2A-deficiency [16]. Similar results were observed after peripheral nerve injury-induced neuropathic pain during the first 7 days (Figure 1). After nerve injury, we did not see a difference in the expression levels of G2A in the DRGs of wild-type mice, compared with untreated mice (Supplementary Figure S2B). However, we observed an increased expression of G2A in BMDMs after stimulation with 9-HODE (Figure 4A). This suggests different actions and pathways involved upon G2A-signaling in various tissues and cell types in pain and inflammation, indicating that the neuronal G2A population does not contribute to SNI-induced neuropathic pain.

Nerve injury-induced neuropathic pain is characterized by a strong inflammatory component, that involves immune cell migration to the injured site of the peripheral nerve [63]. Previous studies have shown a recruitment of immune cells into the spinal cord, beginning 3 days after SNI, as well as the upregulation of pro-inflammatory factors, such as IL-6, lasting for over 21 days [41, 47, 64]. Here, we demonstrated that G2A-deficient mice showed a strongly reduced infiltration of immune cells at the site of injury. Consistent with our findings, earlier studies also showed a reduced number of macrophages at the inflammatory site during peripheral inflammatory pain [22]. Interestingly, in dextran sulfate sodium (DSS)-induced colitis, a reduced number of T cells was observed in G2A-deficient mice, confirming our data of the sciatic nerve after nerve injury (Figure 2C) [65]. Overall, these results suggest that G2A-signaling may depend on the type and location of inflammation as well as release and distribution of signaling lipids in the respective tissues [66].

The G2A receptor seems to influence migration of macrophages since it is able to change cell morphology and cytoskeleton structure [23]. These observations are in line with our data. The most prominent group of proteins being upregulated in macrophages after G2A activation are migratory proteins, as well as proteins responsible for cytoskeleton remodeling. Here, after 9-HODE stimulation,
we could show upregulated G2A expression in macrophages but not in DRGs (Figure 4A, Supplementary Figure S2).

MMP9 is known to play a crucial role in the development of neuropathic pain and inflammation [67]. Indeed, we could observe that MMP9 release is transiently increased during the first 10 h after 9-HODE-induced G2A activation in BMDMs. However, 24 h after G2A activation, we observed decreased MMP9 levels in macrophage cell lysates. This indicates that MMP9 release is increased within the first hours after G2A activation but is saturated 24 h after G2A activation, leaving low intracellular concentrations at this timepoint.

Moreover, we found MyD88, transgelin, PI3K-components and Akt1 to be strongly upregulated in our proteome screen 24 h after G2A activation (Figure 5), which is in good agreement with earlier studies [64]. These proteins all belong to the TLR4 signaling pathway, that is known to promote leukocyte migration and cause release of TNFα and IL-6, both of which we found strongly reduced in G2A-deficient mice (Figure 3B,C) [68–70]. MMP9 is also a downstream target of TLR4 signaling [71]. The transiently increased secretion of MMP9 during the first 10 h of G2A activation is in line with pro-migratory events through TLR4 signaling. According to our data, we therefore propose that G2A activation in macrophages initiates MyD88-PI3K-AKT signaling, transient MMP9 release, as well as TNFα and IL-6 expression and a potential crosstalk with PTK7-Wnt signaling to initiate cytoskeleton remodeling and migration. This is also in good agreement with the data of the proteome screen, wherein MyD88 was not differentially regulated in G2A-deficient bone marrow-derived macrophages (Figure 5B).

However, the study faces several limitations since the proteome analysis data was performed with bone marrow-derived macrophages stimulated in vitro with 9-HODE. Moreover, it is unclear whether these results can be translated to ameliorate neuropathic pain in patients.

Thus, we showed that the immune response is strongly reduced in G2A-deficient mice through a strong reduction of migrated immune cells and reduced concentrations of proinflammatory cytokines, like TNFα and IL-6, at the site of injury (Figure 3B,C).

It is known that IL-1β, IFN-γ, IL-17, IL-6 and TNFα are increased in nervous tissue in animal models of neuropathic pain, but also in cerebrospinal fluid and blood of patients with neuropathic pain [72,73]. Of those, especially IL-6 and TNFα seem to play crucial roles in the initiation of neuropathic pain, in activation of macrophages and in pain processing through sensitization of the TRPV1 channel [74,75]. However, the heterogeneity of neuropathic pain syndromes in patients, the individual differences in disease progression and the differences in investigated liquor or tissue makes it difficult to compare animal and patient studies and to identify specific markers for neuropathic pain.

In the present study, G2A-deficiency resulted in a reduction of IL-6 and TNFα (Figure 3B,C). The decreased amount is likely due to reduced immune cell infiltrates at the site of injury. Furthermore, it was shown that TNFα, IL-6 and IL-12 were increased in G2A-deficient macrophages in atherosclerosis [76]. However, this study was performed in double knockout mice for G2A and ApoE [76] and the strongly reduced macrophage infiltrates observed in our system may easily compensate for a relative increase in inflammatory cytokine production by individual cells. Such different observations may also be explained by the pleiotropic effects of G2A in different inflammatory environments. Thus, Kern and colleagues did not find any difference in the amount of 9-HODE at the inflammatory site, whereas in an earlier study, 9-HODE induced production of IL-6, indicating an important role of the 9-HODE–G2A axis during inflammatory processes [22,77].

5. Conclusions

We could demonstrate that G2A is a crucial component in the initiation of inflammation after nerve injury and thus contributes to neuropathic pain. Furthermore, we showed that G2A-deficiency leads to a strong reduction of macrophage migration to the location of the injured nerve, probably via reduction of TLR4-MyD88-PI3K-AKT and MMP9 signaling and a potential crosstalk with PTK7-Wnt signaling, leading to decreased TNFα and IL-6 levels at the site of injury.
The treatment of neuropathic pain is complex, and so far, sufficient medication is not available [78]. Clinical trials dealing with TNFα or IL-6 inhibitors did not show conclusive and persuasive results [73]. Thus, G2A may represent a promising new target, by inhibitors or antibodies against G2A, and thereby preventing leukocyte migration and peripheral sensitization, especially at the onset of nerve injury-induced neuropathic pain in patients. While, generally, off-target effects of systemic G2A-inhibitors cannot be excluded, they should mainly target G2A receptors in leukocytes where the receptor shows by far its highest expression [23] and other cell types should not be strongly affected by these substances.

However, further preclinical studies are required to assess potential side effects of inhibiting G2A in patients. G2A-inhibitors may have a profile of side effects that is similar to immunosuppressants, which is mainly characterized by a higher risk of infections. We therefore consider treatment with G2A-inhibitors to be carefully monitored and to be restricted to the onset of nerve injury-induced neuropathic pain.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2073-4409/9/7/1740/s1, Figure S1: Activated astrocytes in spinal cord 7d after SNI, Figure S2: Cytokine and chemokine production in nervous tissue after SNI surgery, Figure S3: Stress reactions in G2A-deficient mice and in BMDMs after stimulation with 9-HODE, Figure S4: Immune cell number, cytokine and chemokine production in nervous tissue 7d after SNI surgery, Figure S5: Effect of 9-HODE on migratory signaling pathways, Table S1: Overview of regulated proteins in wild-type BMDMs treated with 1 µM 9-HODE for 24 h, Table S2: Overview of regulated proteins in untreated G2A-deficient and wild-type BMDMs.

**Author Contributions:** T.O. and M.S. did the in vivo experiments and were responsible for all data and figures. V.R., T.O. and B.Z. did the FACS preparations and analyses. P.M. and A.W. performed FACS sorting and analyses. T.O. and B.Z. performed and analyzed the LUMINEX Multiplex analyses. T.O., M.S., K.K., and C.M. designed, and K.K. performed the proteomics experiments. T.O. and K.S (Karin Schilling) designed the experiments and wrote the paper. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the grants SFB1039 A09, B06 and Z01 of the DFG (German Research Foundation), from the State of Hessen to the LOEWE Research Centre for Translational Medicine and Pharmacology, and the Fraunhofer Foundation Project: Neuropathic Pain as well as the DFG Emmy Noether Programme U4216/1-1

**Acknowledgments:** We thank the Quantitative Proteomics Unit at IBC2 for proteomics support, as well as the FACS unit at IBC1.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Colloca, L.; Ludman, T.; Bouhassira, D.; Baron, R.; Dickenson, A.H.; Yarnitsky, D.; Freeman, R.; Truini, A.; Attal, N.; Finnerup, N.B.; et al. Neuropathic pain. *Nat. Rev. Dis. Primers* **2017**, *3*, 17002. [CrossRef] [PubMed]
2. Costigan, M.; Scholz, J.; Woolf, C.J. Neuropathic pain. *Annu. Rev. Neurosci.* **2009**, *32*, 1–32. [CrossRef] [PubMed]
3. Von Hehn, C.A.; Baron, R.; Woolf, C.J. Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms. *Neuron* **2012**, *73*, 638–652. [CrossRef]
4. Liedgens, H.; Obradovic, M.; de Courcy, J.; Holbrook, T; Jakubanis, R. A burden of illness study for neuropathic pain in Europe. *Clinicoecon Outcomes Res.* **2016**, *8*, 113–126. [CrossRef] [PubMed]
5. O’Connor, A.B.; Dworkin, R.H. Treatment of neuropathic pain. *Am. J. Med.* **2009**, *122*, S22–S32. [CrossRef] [PubMed]
6. Basbaum, A.I.; Bautista, D.M.; Scherrer, G.; Julius, D. Cellular and molecular mechanisms of pain. *Cell* **2009**, *139*, 267–284. [CrossRef]
7. Vallejo, R.; Tilley, D.M.; Vogel, L.; Benyamin, R. The role of glia and the immune system in the development and maintenance of neuropathic pain. *Pain Pract.* **2010**, *10*, 167–184. [CrossRef]
8. White, F.A.; Feldman, P.; Miller, R.J. Chemokine signaling and the management of neuropathic pain. *Mol. Interv.* **2009**, *9*, 188–195. [CrossRef]
9. Ji, R.R.; Nackley, A.; Huh, Y.; Terrando, N.; Maixner, W. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. *Anesthesiology* **2018**. [CrossRef]
10. Kiguchi, N.; Kobayashi, Y.; Kishioka, S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. *Curr. Opin. Pharmacol.* **2012**, *12*, 55–61. [CrossRef]

11. Ji, R.R.; Kohno, T.; Moore, K.A.; Woolf, C.J. Central sensitization and LTP. *Trends Neurosci.* **2003**, *26*, 696–705. [CrossRef] [PubMed]

12. Julius, D.; Basbaum, A.I. Molecular mechanisms of nociception. *Nature* **2001**, *413*, 203–210. [CrossRef] [PubMed]

13. Woolf, C.J.; Walters, E.T. Common patterns of plasticity contributing to nociceptive sensitization in mammals and Aplysia. *Trends Neurosci.* **1991**, *14*, 74–78. [CrossRef]

14. Campbell, J.N.; Meyer, R.A. Mechanisms of neuropathic pain. *Neuron* **2006**, *52*, 77–92. [CrossRef]

15. Osthues, T.; Sisignano, M. Oxidized Lipids in Persistent Pain States. *Front. Pharmacol.* **2019**, *10*. [CrossRef]

16. Hohmann, S.W.; Angioni, C.; Tunaru, S.; Lee, S.; Woolf, C.J.; Offermanns, S.; Geisslinger, G.; Scholich, K.; Sisignano, M. The G2A receptor (GPR132) contributes to oxaliplatin-induced mechanical pain hypersensitivity. *Sci. Rep.* **2017**, *7*, 446. [CrossRef]

17. Patwardhan, A.M.; Scotland, P.E.; Akopian, A.N.; Hargreaves, K.M. Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 18820–18824. [CrossRef]

18. Kwan, H.-Y.; Huang, Y.; Yao, X. TRP channels in endothelial function and dysfunction. *Biochim. Biophys. Acta* **2007**, *1772*, 907–914. [CrossRef]

19. Murakami, N.; Yokomizo, T.; Okuno, T.; Shimizu, T. G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. *J. Biol. Chem.* **2004**, *279*, 42484–42491. [CrossRef]

20. Radu, C.G.; Yang, L.V.; Riedinger, M.; Au, M.; Witte, O.N. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 245–250. [CrossRef]

21. Foster, J.R.; Ueno, S.; Chen, M.X.; Harvey, J.; Dowell, S.J.; Irving, A.J.; Brown, A.J. N-Palmitoylglycine and other N-acylamides activate the lipid receptor G2A/GPR132. *Pharmacol. Res. Perspect.* **2019**, *7*, e00542. [CrossRef] [PubMed]

22. Kern, K.; Schäfer, S.M.G.; Cohnen, J.; Pierre, S.; Osthues, T.; Tarighi, N.; Hohmann, S.; Ferreiros, N.; Brüne, B.; Weigert, A.; et al. The G2A Receptor Controls Polarization of Macrophage by Determining Their Localization Within the Inflamed Tissue. *Front. Immunol.* **2018**, *9*, 2261. [CrossRef] [PubMed]

23. Yang, L.V.; Radu, C.G.; Wang, L.; Riedinger, M.; Witte, O.N. GI-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. *Blood* **2005**, *105*, 1127–1134. [CrossRef]

24. Peter, C.; Waibel, M.; Radu, C.G.; Yang, L.V.; Witte, O.N.; Schulze-Osthoff, K.; Wesselborg, S.; Lauber, K. Migration to apoptotic “find-me” signals is mediated via the phagocyte receptor G2A. *J. Biol. Chem.* **2008**, *283*, 5296–5305. [CrossRef] [PubMed]

25. Le, L.Q.; Kabarowski, J.H.; Weng, Z.; Satterthwaite, A.B.; Harvill, E.T.; Jensen, E.R.; Miller, J.F.; Witte, O.N. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. *Immunity* **2001**, *14*, 561–571. [CrossRef]

26. Andrews, N.A.; Latremoliere, A.; Basbaum, A.I.; Mogil, J.S.; Porreca, F.; Rice, A.S.; Woolf, C.J.; Currie, G.L.; Dworkin, R.H.; Eisenach, J.C.; et al. Ensuring transparency and minimization of methodologic bias in preclinical pain research. *Pain* **2016**, *157*, 901–909. [CrossRef]

27. Decosterd, I.; Woolf, C.J. Spared nerve injury. *Pain* **2000**, *87*, 149–158. [CrossRef]

28. Sisignano, M.; Park, C.K.; Angioni, C.; Zhang, D.D.; von Hehn, C.; Cobos, E.J.; Ghasemlou, N.; Xu, Z.Z.; Kumaran, V.; Lu, R.; et al. 5,6-EET is released upon neuronal activity and induces mechanical pain hypersensitivity via TRPA1 on central afferent terminals. *J. Neurosci.* **2012**, *32*, 6364–6372. [CrossRef]

29. Kallenborn-Gerhardt, W.; Hohmann, S.W.; Syhr, K.M.; Schroder, K.; Sisignano, M.; Weigert, A.; Lorenz, J.E.; Lu, R.; Brune, B.; Brandes, R.P.; et al. Nox2-dependent signaling between macrophages and sensory neurons contributes to neuropathic pain hypersensitivity. *Pain* **2014**, *155*, 2161–2170. [CrossRef]

30. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) Method. *Methods* **2001**, *15*, 402–408. [CrossRef]

31. Schmitz, K.; Wilken-Schmitz, A.; Vasic, V.; Brunkhorst, R.; Schmidt, M.; Tegeder, I. Progranulin deficiency confers resistance to autoimmune encephalomyelitis in mice. *Cell Mol. Immunol.* **2019**. [CrossRef]

32. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **1976**, *72*, 248–254. [CrossRef]
33. Münch, C.; Harper, J.W. Mitochondrial unfolded protein response controls matrix pre-RNA processing and translation. *Nature* 2016, 534, 710–713. [CrossRef] [PubMed]
34. Perez-Riverol, Y.; Csordas, A.; Bai, J.; Bernal-Linares, M.; Hewapathirana, S.; Kandu, D.J.; Inuganti, A.; Griss, J.; Mayer, G.; Eisenacher, M.; et al. The PRIDE database and related tools and resources in 2019: Improving support for quantification data. *Nucleic Acids Res.* 2019, 47, D442–D450. [CrossRef] [PubMed]
35. Schuh, C.D.; Brenneis, C.; Zhang, D.D.; Angioni, C.; Schreiber, Y.; Ferreiros-Bouzas, N.; Pierre, S.; Henke, M.; Linke, B.; Nusing, R.; et al. Prostacyclin regulates spinal nociceptive processing through cyclic adenosine monophosphate-induced translocation of glutamate receptors. *Anesthesiology* 2014, 120, 447–458. [CrossRef] [PubMed]
36. Taylor, S.C.; Berkelman, T.; Yadav, G.; Hammond, M. A defined methodology for reliable quantification of Western blot data. *Mol. Biotechnol.* 2013, 55, 217–226. [CrossRef]
37. Weigert, A.; Weichand, B.; Sekar, D.; Sha, W.; Hahn, C.; Mora, J.; Ley, S.; Essler, S.; Dehne, N.; Brüne, B. HIF-1α is a negative regulator of plasmacytoid DC development in vitro and in vivo. *Blood* 2012, 120, 3001–3006. [CrossRef] [PubMed]
38. Sisignano, M.; Angioni, C.; Park, C.K.; Meyer Dos Santos, S.; Jordan, H.; Kuzikov, M.; Liu, D.; Zinn, S.; Hohman, S.W.; Schreiber, Y.; et al. Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. *Proc. Natl. Acad. Sci. USA* 2016, 113, 12544–12549. [CrossRef]
39. Justus, C.R.; Dong, L.; Yang, L.V. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. *Front. Physiol.* 2013, 4, 354. [CrossRef]
40. Scholz, J.; Woolf, C.J. The neuropathic pain triad. *Nat. Neurosci.* 2007, 10, 1361–1368. [CrossRef]
41. Costigan, M.; Moss, A.; Latremoliere, A.; Johnston, C.; Verma-Gandhu, M.; Herbert, T.A.; Barrett, L.; Brenner, G.J.; Vardeh, D.; Woolf, C.J.; et al. T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. *J. Neurosci.* 2009, 29, 14415–14422. [CrossRef] [PubMed]
42. Sisignano, M.; Bennett, D.L.; Geisslinger, G.; Scholich, K. TRP-channels as key integrators of lipid pathways in nociceptive neurons. *Prog. Lipid Res.* 2014, 53, 93–107. [CrossRef] [PubMed]
43. Lahvic, J.L.; Ammerman, M.; Li, P.; Blair, M.C.; Stillman, E.R.; Fast, E.M.; Robertson, A.L.; Christodoulou, C.; Perlin, J.R.; Yang, S.; et al. Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132. *Proc. Natl. Acad. Sci. USA* 2018, 115, 9252–9257. [CrossRef]
44. Inceoglu, B.; Jinks, S.L.; Schmelzer, K.R.; Waite, T.; Kim, I.H.; Hammock, B.D. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. *Life Sci.* 2006, 79, 2311–2319. [CrossRef] [PubMed]
45. Zimmer, B.; Angioni, C.; Osthues, T.; Toewe, A.; Thomas, D.; Pierre, S.C.; Geisslinger, G.; Scholich, K.; Sisignano, M. The oxidized linoleic acid metabolite 12,13-DiHOME mediates thermal hyperalgesia during inflammatory pain. *Biochim. Biophys. Acta Mol. Cell. Biol. Lipids* 2009, 1795, 56–65. [CrossRef]
46. Vega-Avelaira, D.; Géranton, S.M.; Fitzgerald, M. Differential regulation of immune responses and macrophage/neuron interactions in the dorsal root ganglion in young and adult rats following nerve injury. *Mol. Pain* 2009, 5, 70. [CrossRef]
47. Cobos, E.J.; Nickerson, C.A.; Gao, F.; Chandran, V.; Bravo-Caparrós, I.; González-Cano, R.; Riva, P.; Andrews, N.A.; Latremoliere, A.; Seehus, C.R.; et al. Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling. *Cell Rep.* 2018, 22, 1301–1312. [CrossRef]
48. Kwon, M.J.; Kim, J.; Shin, H.; Jeong, S.R.; Kang, Y.M.; Choi, J.Y.; Hwang, D.H.; Kim, B.G. Contribution of Macrophages to Enhanced Regenerative Capacity of Dorsal Root Ganglia Sensory Neurons by Conditioning Injury. *J. Neurosci.* 2013, 33, 15095–15108. [CrossRef]
49. Lindborg, J.A.; Niemi, J.P.; Howarth, M.A.; Liu, K.W.; Moore, C.Z.; Mahajan, D.; Zigmond, R.E. Molecular and cellular identification of the immune response in peripheral ganglia following nerve injury. *J. Neuroinflamm.* 2018, 15, 1–17. [CrossRef]
50. Dubový, P.; Klusáková, I.; Hradilová-Sviženská, I.; Joukal, M.; Boadas-Vaello, P. Activation of Astrocytes and Microglial Cells and CCL2/CCR2 Uregulation in the Dorsolateral and Ventrolateral Nuclei of Periaqueductal Gray and Rostral Ventromedial Medulla Following Different Types of Sciatic Nerve Injury. *Front. Cell Neurosci.* 2018, 12, 40. [CrossRef]
51. Ji, R.R.; Xu, Z.Z.; Gao, Y.J. Emerging targets in neuroinflammation-driven chronic pain. *Nat. Rev. Drug. Discov.* 2014, 13, 533–548. [CrossRef] [PubMed]
52. Hamill, K.J.; Hiroyasu, S.; Colburn, Z.T.; Ventrelle, R.V.; Hopkinson, S.B.; Skalli, O.; Jones, J.C.R. Alpha actinin-1 regulates cell-matrix adhesion organization in keratinocytes: Consequences for skin cell motility. *J. Investig. Dermatol.* 2015, 135, 1043–1052. [CrossRef] [PubMed]

53. Hägerbrand, K.; Westlund, J.; Yrlid, U.; Agace, W.; Johansson-Lindbom, B. MyD88 Signaling Regulates Steady-State Migration of Intestinal CD103+ Dendritic Cells Independently of TNF-α and the Gut Microbiota. *J. Immunol.* 2015, 195, 2888–2899. [CrossRef] [PubMed]

54. Vanhaesebroeck, B.; Guillermert-Guibert, J.; Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. *Nat. Rev. Mol. Cell Biol.* 2010, 11, 329–341. [CrossRef]

55. Vermeulen, S.J.; Nollet, F.; Teugels, E.; Krist'l, M.V.; Malfait, F.; Philippé, J.; Speelman, F.; Bracke, M.E.; van Roy, F.M.; Mareel, M.M. The αβ-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells. *OncoGene* 1999, 18, 905–915. [CrossRef]

56. Chaunhan, S.K.; Lee, H.K.; Lee, H.S.; Park, E.Y.; Jeong, E.; Dana, R. PTK7+ Mononuclear Cells Express VEGFR2 and Contribute to Vascular Stabilization by Upregulating Angiopoietin-1. *Arterioscler. Thromb. Vasc. Biol.* 2015, 35, 1606–1615. [CrossRef]

57. Lee, H.K.; Chaunhan, S.K.; Kay, E.; Dana, R. Fli-1 regulates vascular endothelial cell migration via a protein tyrosine kinase-7-dependent pathway. *Blood* 2011, 117, 5762–5771. [CrossRef]

58. Kleinsimon, S.; Longmuss, E.; Rolf, J.; Jäger, S.; Eggert, A.; Delebinski, C.; Seifert, G. GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway. *Sci. Rep.* 2018. [CrossRef]

59. Chwieralski, C.E.; Welte, T.; Bühling, F. Cathepsin-regulated apoptosis. *Apoptosis* 2006, 11, 143–149. [CrossRef]

60. Webb, A.H.; Gao, B.T.; Goldsmith, Z.K.; Irvine, A.S.; Saleh, N.; Lee, R.P.; Lendermon, J.B.; Bheemreddy, R.; Chwieralski, C.E.; Welte, T.; Bühling, F. Cathepsin-regulated apoptosis. *Apoptosis* 2006, 11, 143–149. [CrossRef]

61. Weng, Z.; Fluckiger, A.-C.; Nisitani, S.; Wahl, M.I.; Le, L.Q.; Hunter, C.A.; Fernal, A.A.; Le Beau, M.M.; van Roy, F.M.; Mareel, M.M. The αβ-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells. *OncoGene* 1999, 18, 905–915. [CrossRef]

62. Laedermann, C.J.; Pertin, M.; Suter, M.R.; Decosterd, I. Voltage-gated sodium channel expression in mouse DRG after SNI leads to re-evaluation of projections of injured fibers. *Mol. Pain* 2014, 10, 19. [CrossRef] [PubMed]

63. Ji, R.-R.; Chamessian, A.; Zhang, Y.-Q. Pain regulation by non-neuronal cells and inflammation. *Science* 2016, 354, 572–577. [CrossRef] [PubMed]

64. Gattlen, C.; Clarke, C.B.; Piller, N.; Kirschmann, G.; Pertin, M.; Decosterd, I.; Gosselin, R.-D.; Suter, M.R. Spinal Cord T-Cell Infiltration in the Rat Spared Nerve Injury Model: A Time Course Study. *Int. J. Mol. Sci.* 2016, 17, 352. [CrossRef]

65. Frasch, S.C.; McNamie, E.N.; Kominsky, D.; Jedlicka, P.; Jakubzick, C.; Zemski Berry, K.; Mack, M.; Furuta, G.T.; Lee, J.J.; Henson, P.M.; et al. G2A Signaling Dampens Colitic Inflammation via Production of IFN-gamma. *J. Immunol.* 2016, 197, 1425–1434. [CrossRef]

66. Parks, B.W.; Black, L.L.; Zimmerman, K.A.; Metz, A.E.; Steele, C.; Murphy-Ullrich, J.E.; Kabarowski, J.H. CD36, but not G2A, modulates eicosanoid expression, chemotaxis, phagocytosis, and oxidative ability via a toll-like receptor 4-dependent pathway: Validated by RNA interference. *Toxicol. Lett.* 2009, 191, 195–202. [CrossRef]

67. Kim, H.-R.; Lee, H.-S.; Lee, K.-S.; Jung, I.D.; Kwon, M.-S.; Kim, C.-H.; Yoon, M.-H.; Park, Y.-M.; Lee, S.-M.; et al. An Essential Role for TAGLN2 in Phagocytosis of Lipopolysaccharide-activated Macrophages. *Sci. Rep.* 2017, 7, 1–13. [CrossRef]

68. Jackson, L.; Cady, C.T.; Cambier, J.C. TLR4-mediated signaling induces MMP9-dependent cleavage of B cell surface CD23. *J. Immunol.* 2009, 183, 2585–2592. [CrossRef]
72. Üçeyler, N.; Rogausch, J.P.; Toyka, K.V.; Sommer, C. Differential expression of cytokines in painful and painless neuropathies. Neurology 2007, 69, 42–49. [CrossRef] [PubMed]
73. Hung, A.L.; Lim, M.; Doshi, T.L. Targeting cytokines for treatment of neuropathic pain. Scand. J. Pain 2017, 17, 287–293. [CrossRef] [PubMed]
74. Zhou, Y.-Q.; Liu, Z.; Liu, Z.-H.; Chen, S.-P.; Li, M.; Shahveranov, A.; Ye, D.-W.; Tian, Y.-K. Interleukin-6: An emerging regulator of pathological pain. J. Neuroinflamm. 2016, 13, 141. [CrossRef] [PubMed]
75. Jin, X.; Gereau, R.W. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J. Neurosci. 2006, 26, 246–255. [CrossRef] [PubMed]
76. Bolick, D.T.; Skaflen, M.D.; Johnson, L.E.; Kwon, S.-C.; Howatt, D.; Daugherty, A.; Ravichandran, K.S.; Hedrick, C.C. G2A Deficiency in Mice Promotes Macrophage Activation and Atherosclerosis. Circ. Res. 2008, 104, 318–327. [CrossRef] [PubMed]
77. Hattori, T.; Obinata, H.; Ogawa, A.; Kishi, M.; Tatei, K.; Ishikawa, O.; Izumi, T. G2A plays proinflammatory roles in human keratinocytes under oxidative stress as a receptor for 9-hydroxyoctadecadienoic acid. J. Investig. Dermatol. 2008, 128, 1123–1133. [CrossRef]
78. Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpää, M.; Hansson, P.; Jensen, T.S.; et al. Pharmacotherapy for neuropathic pain in adults. Lancet Neurol. 2015, 14, 162–173. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).